Haemophilia drug raises CSL outlook for 2022-2023
MELBOURNE: Broker Wilsons values CSL’s drug development pipeline at $62 per share and ...
To read the full story...SUBSCRIBE NOWExisting Subscribers Login Below:
Log In
